We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Sensyne Health Plc | SENS | London | Ordinary Share |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 0.35 | 01:00:00 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 0.35 | 0.35 |
| Top Posts |
|---|
Posted at 02/7/2022 13:38 by wanna brew Offerhttps://www.sen |
Posted at 16/6/2022 11:26 by wanna brew No RNS yet to confirm tomorrow is last day of trading. I guess that will be 0700 hrs tomorrow. Lmso if some corporate action soon after delisting. But as in for the long term it doesn't really matter, hopefully Snow can turn things around and in a year or two re-list or have a buyer. I guess that's what the Institutional investors are banking on. |
Posted at 23/4/2022 10:31 by bob1995 BIG CEO comes to a company with a 2 million mcap. previously sold and funding for 100s million. make no mistake this guy is not here for a simple handshake. Exscientia, the innovative company at the forefront of Artificial Intelligence (AI)-driven drug discovery, is pleased to announce the appointment of Mr Alex Snow to its Board of Directors as Deputy Chairman. He brings significant strategic development and financial experience to the board.Alex is an experienced investor, banker and entrepreneur, having previously founded Oxford Sciences Innovation (OSI) and raised more than £600 million to commercialise world-leading science originating at Oxford University. |
Posted at 12/2/2022 14:26 by billy3 Stinger.I agree with all the above. From previous announcments Sens have lots of deals ready to go and more on the way. I think their revenue projections are probably on track but its the delay that has caused the problem. Revnue is a year behind. Any buyer will be aware (through due diligence) of the contracts signed and in the pipeline so will know the value looking ahead. Although Sens haven't made money yet, the value is also in what has been spent as the buyer will get a company that has had to invest millions to get where it is. One good thing is that there won't be too many private investors in now. Many have jumped ship. I also suspect that many who got in low 20's wanted to double in a week so got out when that didn't happen. Any increase in share price was never going to happen till the company gets an offer. The investment companies are in this still and supportive. They had to support the cash call otherwise they'd get back the result of a sale after the company went in to administration. Timeline wise, I hope and woud expect a deal this month. |
Posted at 07/2/2022 09:28 by madcapinvestor The lock-up agreement is based mainly on specific terms being met, which is ideal for real investors here as it means all the institutions with the exception of PEEL, were willing to be lock in millions until there is a specific outcome that will benefit all genuine holders here. If we lose, then they will lose too. It's actually extremely reassuring for genuine investors like myself, hence my confidence. It should also be of extreme concern to morons like yourself, shorting a stock that's just dropped 80%, has just secured major funding from institutions, is trading at the bottom, and is weeks/months away from getting a deal across the line. |
Posted at 28/1/2022 11:45 by caucic AgreeBtw Who will be responsible for deciding/confirming the sale price? Apart from the BOD, are the other major Instit. Investors involved in the decision? |
Posted at 25/1/2022 08:39 by p1nkfish I invest madcap, its called research.A quiest PBB is very indicative of a lack of speculators and an increase in investors. Try it some time. Very profitable. |
Posted at 23/1/2022 08:13 by keya5000 But three and a half years later, the party appears to be over. Following a bumpy stint on Aim Sensyne’s value crashed earlier this month to less than £30m. Lord Drayson is now attempting to manoeuvre a sharp U-turn off the markets, through a management buyout or an outright sale.Time has not been not on Sensyne’s side. Money has been fast running out. Investors have, in principle, agreed to £6.4m in emergency fundraising, with the potential for a further £5m. Earlier this month it admitted that “whilst the board believes the financing will proceed to completion in the near term, without it the company is unlikely to be able to continue to trade beyond early February 2022, by which time the formal sale process won’t have completed”. The Telegraph understands such a deal will be completed within days. |
Posted at 16/1/2022 12:21 by 40 fathoms Yes, he claims to be ethical and I am always suspicious of those who tell you rather than show you.As I said earlier this is not for 90% of investors but what is clear from some of the comments here is that they have not properly read the RNS and do not understand how much money is chasing good assets in this space. Once again I would put it to you that JP Morgan is running the FSP, this is a global bulge bracket investment bank. They do not take on mandates where they can not see their way to making substantial fees. So clearly they feel/felt that their is a significant level of intrinsic value in the business. You will also see that they said there is interest both from corporates and from financial sponsors. I think this is interesting as it demonstrates private equity interest as well. A deal is a certainty in my view, the question then becomes what is the price once again I am certain it will be much, much, much higher than Fridays closing price. I am happy to take substantial profits if I am right and cede the I told you so bragging rights if I am wrong. |
Posted at 28/7/2021 14:49 by billy3 Small recent rise partly helped by tip in the Telegraph.Four of the fastest-growing stocks investors should buyExperts predict these companies will offer big rewards to adventurous investorsTrying to find the fastest-growing stocks in the hope they will become world-leading companies is not the right strategy for every investor. But for those investing for the long term, who can stomach violent share price swings, the rewards can be immense.Buying the right companies is no easy task, however. “Growth” investors search for companies that are growing their sales substantially every year. While they may not always be profitable, investors in these companies are betting that by getting in early, they will reap big rewards when their strong growth leads to profits.It can be a risky strategy, but fund managers believe the following stocks boast both the strong sales growth and resilient business models needed to make them compelling investments.Sensyne HealthBritish healthcare technology firm Sensyne Health uses anonymous patient data to accelerate the development of new medicines.Neil Goddin, manager of the Artemis Positive Future fund, said Sensyne was changing how drugs were developed and the treatment given to sick patients. "It has over 10 apps being used today, ranging from self-monitoring of blood glucose levels and coronavirus monitoring, right through to monitoring of heart failure. Now revenues are really taking off,” he said.The first year of sales – 2018 – generated £81,000 in revenue. In 2019 this grew by 68pc, before explosive growth last year, when revenue surged 1,500pc to more than £2m. By the end of 2024 sales are expected to have risen to £80m, according to Mr Goddin.Sensyne's share price performance offers a glimpse of how volatile growth stocks can be, however. After floating in 2018 at 175p per share, they tumbled to a low of just over 31p, before rising nearly five-fold to today's 150p price. |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
